Controversies in the management of stage IIIA non-small-cell lung cancer Article

Santos, ES, Castrellon, A, Blaya, M et al. (2008). Controversies in the management of stage IIIA non-small-cell lung cancer . EXPERT REVIEW OF ANTICANCER THERAPY, 8(12), 1913-1929. 10.1586/14737140.8.12.1913

cited authors

  • Santos, ES; Castrellon, A; Blaya, M; Raez, LE



  • New developments in the management of non-small-cell lung cancer, as well as recent proposals for changing the current lung cancer staging system, are posing a challenge in the therapeutic decision making regarding this disease. For the last two decades, the management of stage IIIA (N2) disease has been controversial and the target for clinical trials has been to determine the best therapeutic approach that may result in better survival outcomes without increasing toxicity. For many years, combined modality treatment (systemic chemotherapy plus radiation therapy) became the standard of care in this setting. However, the poor outcomes seen with combined modality for N2 has obligated us to explore other possibilities. In this sense, recent clinical trials in the neoadjuvant setting using chemotherapy alone or combined modality are providing fruitful results and shifting the paradigm on this stage. A recent, large randomized multicenter trial argues against what has slowly become a current practice in some centers - the use of preoperative modality for N2 disease. Another controversy that we will discuss here is the acceptance of adjuvant therapy for resected stage IB-IIIA non-small-cell lung cancer. It was not long ago that adjuvant radiation therapy was still the standard of care for patients who have pathological nodal disease. We will present the current data on these debatable issues and how to implement this new knowledge into clinical practice. © 2008 Expert Reviews Ltd.

publication date

  • December 1, 2008

published in

Digital Object Identifier (DOI)

start page

  • 1913

end page

  • 1929


  • 8


  • 12